CR20190251A - Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f - Google Patents

Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f

Info

Publication number
CR20190251A
CR20190251A CR20190251A CR20190251A CR20190251A CR 20190251 A CR20190251 A CR 20190251A CR 20190251 A CR20190251 A CR 20190251A CR 20190251 A CR20190251 A CR 20190251A CR 20190251 A CR20190251 A CR 20190251A
Authority
CR
Costa Rica
Prior art keywords
trifluoro
compositions
pyridinoylpiperidine
agonists
methods related
Prior art date
Application number
CR20190251A
Other languages
English (en)
Inventor
Emma Sharp
Paul Fagan
Raymond D Skwierczynski
Brigida Allieri
Original Assignee
Colucid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20190251(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc
Publication of CR20190251A publication Critical patent/CR20190251A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20190251A 2016-12-06 2017-12-05 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f CR20190251A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430662P 2016-12-06 2016-12-06
PCT/US2017/064652 WO2018106657A1 (en) 2016-12-06 2017-12-05 Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Publications (1)

Publication Number Publication Date
CR20190251A true CR20190251A (es) 2019-08-26

Family

ID=60972336

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190251A CR20190251A (es) 2016-12-06 2017-12-05 Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f

Country Status (38)

Country Link
US (1) US11053214B2 (es)
EP (1) EP3551617B1 (es)
JP (4) JP2020500936A (es)
KR (4) KR20250070124A (es)
CN (3) CN115385894A (es)
AU (1) AU2017373784B2 (es)
BR (1) BR112019010934A2 (es)
CA (1) CA3043772C (es)
CL (1) CL2019001426A1 (es)
CO (1) CO2019005290A2 (es)
CR (1) CR20190251A (es)
CY (1) CY1124540T1 (es)
DK (1) DK3551617T3 (es)
DO (1) DOP2019000139A (es)
EA (1) EA201991112A1 (es)
EC (1) ECSP19040190A (es)
ES (1) ES2889476T3 (es)
HR (1) HRP20211557T1 (es)
HU (1) HUE056820T2 (es)
IL (1) IL266598B2 (es)
JO (1) JOP20190129B1 (es)
LT (1) LT3551617T (es)
MA (1) MA52920B1 (es)
MD (1) MD3551617T2 (es)
MX (2) MX392547B (es)
MY (1) MY196855A (es)
NZ (1) NZ752906A (es)
PE (2) PE20241297A1 (es)
PH (1) PH12019501252B1 (es)
PL (1) PL3551617T3 (es)
PT (1) PT3551617T (es)
RS (1) RS62415B1 (es)
SI (1) SI3551617T1 (es)
TN (1) TN2019000174A1 (es)
TW (1) TWI671290B (es)
UA (1) UA124433C2 (es)
WO (1) WO2018106657A1 (es)
ZA (1) ZA201903449B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010359A (es) 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
US12271057B1 (en) 2019-12-20 2025-04-08 The Uab Research Foundation Chromatic aberration tuning ophthalmic corrector lens methods
EP4333815A1 (en) 2021-05-07 2024-03-13 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro- n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2- ylj-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
MX2011010359A (es) * 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
US8697876B2 (en) 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
US20140221385A1 (en) 2011-06-01 2014-08-07 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
CN114213393A (zh) 2016-07-15 2022-03-22 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Also Published As

Publication number Publication date
KR20190075130A (ko) 2019-06-28
PH12019501252B1 (en) 2024-05-24
JP2020500936A (ja) 2020-01-16
CN115385894A (zh) 2022-11-25
EP3551617B1 (en) 2021-08-11
JOP20190129A1 (ar) 2019-05-29
IL266598A (en) 2019-07-31
JP2023123678A (ja) 2023-09-05
CL2019001426A1 (es) 2019-10-11
JP2024178323A (ja) 2024-12-24
TWI671290B (zh) 2019-09-11
SI3551617T1 (sl) 2021-11-30
MX392547B (es) 2025-03-24
TN2019000174A1 (en) 2020-10-05
NZ752906A (en) 2021-07-30
JP2022000451A (ja) 2022-01-04
CO2019005290A2 (es) 2019-05-31
CA3043772C (en) 2022-06-07
MY196855A (en) 2023-05-05
ECSP19040190A (es) 2019-08-30
UA124433C2 (uk) 2021-09-15
KR20230008257A (ko) 2023-01-13
IL266598B1 (en) 2024-01-01
CA3043772A1 (en) 2018-06-14
PT3551617T (pt) 2021-10-04
CN110291079A (zh) 2019-09-27
HRP20211557T1 (hr) 2022-01-07
ES2889476T3 (es) 2022-01-12
ZA201903449B (en) 2021-02-24
TW201833097A (zh) 2018-09-16
JP7561240B2 (ja) 2024-10-03
KR20210102497A (ko) 2021-08-19
BR112019010934A2 (pt) 2019-10-01
US20200087279A1 (en) 2020-03-19
PE20241297A1 (es) 2024-06-24
CY1124540T1 (el) 2022-07-22
MX388091B (es) 2025-03-19
RS62415B1 (sr) 2021-10-29
MD3551617T2 (ro) 2021-12-31
JP7818666B2 (ja) 2026-02-20
DK3551617T3 (da) 2021-09-13
MX2021014139A (es) 2022-05-24
KR20250070124A (ko) 2025-05-20
EP3551617A1 (en) 2019-10-16
PH12019501252A1 (en) 2019-12-02
MX2019006520A (es) 2019-08-21
MA52920A (fr) 2021-04-28
PL3551617T3 (pl) 2021-12-20
HUE056820T2 (hu) 2022-03-28
AU2017373784A1 (en) 2019-05-16
IL266598B2 (en) 2024-05-01
WO2018106657A1 (en) 2018-06-14
DOP2019000139A (es) 2019-08-15
US11053214B2 (en) 2021-07-06
AU2017373784B2 (en) 2020-04-23
JOP20190129B1 (ar) 2023-03-28
LT3551617T (lt) 2021-10-11
CN115385893A (zh) 2022-11-25
MA52920B1 (fr) 2021-11-30
EA201991112A1 (ru) 2019-10-31
PE20191134A1 (es) 2019-09-02

Similar Documents

Publication Publication Date Title
CR20190251A (es) Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht 1f
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CL2019001344A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
EA201691134A1 (ru) Новые ингибиторы глутаминазы
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MY202008A (en) Crystalline and salt forms of ppar agonist compounds
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CO2019014647A2 (es) Composiciones inmunogénicas
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
MX382453B (es) Composiciones y metodos para tratar enfermedades neurodegenerativas
CL2019001649A1 (es) Método para el control de enfermedades bacterianas de plantas utilizando derivados de carboxamida.
MX394254B (es) Composiciones para el tratamiento de dermatitis atópica canina y sus usos.
BR112018006422A2 (pt) composições e métodos para inibir beta-lactamase
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
BR112017004552A2 (pt) composições farmacêuticas
MX2019005294A (es) Inhibidores de las interacciones de mtor-deptor y metodos de uso de los mismos.
MX393805B (es) Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos.
BR112018074231A2 (pt) compostos bicíclicos fundidos para o tratamento de doença